Astellas Pharma (China)

Astellas Pharma (China)

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. Astellas is a member of the Mitsubishi UFJ Financial Group keiretsu. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Astellas Pharma (China), China, covering academic research published from 2000 to 2024. Read More.


Open Access Percentage

51%


Total
Publications

264


Total Open
Publications

135


Total
Citations

12K


Open Access
Percentage

51%


Total
Publications

264


Total Open
Publications

135


Total
Citations

12K

Wikipedia

Website

download

Breakdown

25% 18% 7% 50%

Publisher Open

25%

Both

18%

Other Platform Open

7%

Closed

50%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

02468101214161820Total Publications
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

35%OA Journal

OA Journal 35%

38

Hybrid 24%

27

No Guarantees 41%

45

Other Platform Open

Domain 78%

51

Institution 20%

13

Other Internet 15%

10

Preprint 0%

0

Public 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
51
DOI
Other Internet
8
Unknown Repository
Other Internet
3
Yonsei University Medical Library - YUHSpace
Institution
1
University of Zaragoza Repository - Zaguan
Institution
1
University of Michigan - Deep Blue
Institution
1
University of Melbourne - Minerva Access
Institution
1
University of Leeds, The University of Sheffield, University of York - White Rose Research Online
Institution
1
University of Cantabria - UCrea
Institution
1
University of Bern - Bern Open Repository and Information System
Institution
1
1 / 2

Data updated 18 August 2025

Share

Share

Share